Maurizio Cutolo Selected Research

Interstitial Lung Diseases (Interstitial Lung Disease)

12/2021	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
1/2021	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
1/2021	Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maurizio Cutolo Research Topics

Disease

100	Rheumatoid Arthritis 01/2022 - 06/2002
38	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 06/2009
23	Inflammation (Inflammations) 02/2022 - 07/2002
21	Rheumatic Diseases (Rheumatism) 02/2022 - 06/2002
17	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2021 - 01/2002
13	Autoimmune Diseases (Autoimmune Disease) 05/2022 - 06/2002
10	Connective Tissue Diseases (Connective Tissue Disease) 05/2022 - 01/2008
10	Arthritis (Polyarthritis) 01/2020 - 02/2005
9	Necrosis 01/2020 - 02/2007
7	Pain (Aches) 10/2018 - 02/2005
6	Disease Progression 10/2020 - 12/2011
6	Osteoarthritis 01/2020 - 12/2003
6	Fibrosis (Cirrhosis) 08/2019 - 10/2010
5	digital ulcers 09/2015 - 01/2010
5	Synovitis 03/2015 - 03/2004
4	Mixed Connective Tissue Disease (MCTD) 01/2022 - 02/2012
4	Undifferentiated Connective Tissue Diseases 01/2022 - 01/2008
4	Raynaud Disease (Raynaud's Disease) 01/2022 - 10/2010
4	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2021 - 05/2015
4	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 09/2018 - 04/2002
4	Infections 11/2017 - 12/2008
4	Neoplasms (Cancer) 11/2014 - 06/2002
3	COVID-19 01/2022 - 12/2020
3	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2021 - 01/2021
3	Insulin Resistance 09/2021 - 10/2007
3	Atherosclerosis 09/2021 - 06/2006
3	Vitamin D Deficiency 02/2021 - 01/2008
3	Psoriatic Arthritis 01/2018 - 04/2010
2	Dermatomyositis (Dermatopolymyositis) 11/2021 - 01/2018
2	Muscular Diseases (Myopathy) 05/2021 - 01/2017
2	Breast Neoplasms (Breast Cancer) 03/2019 - 03/2018
2	Pulmonary Arterial Hypertension 01/2018 - 01/2010
2	Pregnancy Complications 01/2018 - 05/2015
2	Osteoporosis 05/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

29	GlucocorticoidsIBA 01/2022 - 04/2002
21	Estrogens (Estrogen)FDA Link 03/2019 - 06/2002
19	CytokinesIBA 02/2022 - 06/2002
17	Vitamin D FDA LinkGeneric 02/2021 - 05/2007
17	Hormones (Hormone)IBA 07/2019 - 04/2002
14	AndrogensIBA 11/2020 - 06/2002
14	Antirheumatic Agents (DMARD)IBA 02/2020 - 06/2010
14	Biological ProductsIBA 01/2020 - 06/2002
13	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 06/2002
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 07/2005
12	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2014 - 06/2002
11	Biomarkers (Surrogate Marker)IBA 09/2021 - 07/2005
11	SteroidsIBA 11/2020 - 04/2002
10	Abatacept (Orencia)FDA Link 12/2021 - 01/2009
9	AutoantibodiesIBA 02/2022 - 01/2010
9	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2017 - 07/2002
9	Prednisone (Sone)FDA LinkGeneric 01/2017 - 01/2009
8	Leflunomide (Arava)FDA LinkGeneric 01/2020 - 05/2009
7	Rituximab (Mabthera)FDA Link 01/2020 - 12/2009
7	Interleukin-6 (Interleukin 6)IBA 09/2018 - 04/2002
6	Adalimumab (Humira)FDA Link 01/2020 - 01/2004
6	Etanercept (Enbrel)FDA Link 01/2020 - 02/2007
6	Infliximab (Remicade)FDA Link 01/2020 - 02/2007
6	tofacitinibIBA 01/2020 - 03/2012
5	beta-cyclodextrin tetradecasulfate (CTDS)IBA 01/2022 - 02/2012
5	Certolizumab Pegol FDA Link 01/2020 - 03/2014
5	Janus Kinase InhibitorsIBA 01/2020 - 03/2012
5	tocilizumab (atlizumab)FDA Link 01/2020 - 04/2013
5	Estrogen ReceptorsIBA 03/2019 - 06/2006
5	Testosterone (Sustanon)FDA Link 03/2019 - 06/2002
4	Monoclonal AntibodiesIBA 12/2021 - 01/2002
4	AntibodiesIBA 01/2020 - 09/2016
4	golimumab FDA Link 01/2020 - 03/2014
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 04/2013
4	Tumor Necrosis Factor InhibitorsIBA 06/2017 - 06/2006
4	ametantrone (HAQ)IBA 05/2017 - 02/2007
4	Bosentan (Tracleer)FDA Link 11/2016 - 05/2014
4	Pharmaceutical PreparationsIBA 05/2016 - 06/2002
4	LipidsIBA 02/2013 - 06/2006
3	Prednisolone (Predate)FDA LinkGeneric 01/2022 - 04/2010
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2014
3	Biosimilar PharmaceuticalsIBA 01/2020 - 03/2014
3	Androstenedione (4 Androstene 3,17 dione)IBA 03/2019 - 06/2006
3	Estradiol (Delestrogen)FDA LinkGeneric 03/2019 - 11/2006
3	Antinuclear AntibodiesIBA 01/2019 - 02/2012
3	apremilastIBA 01/2018 - 01/2016
3	25-hydroxyvitamin DIBA 05/2017 - 03/2011
3	hydroxide ionIBA 05/2017 - 05/2014
3	Aromatase (CYP19)IBA 05/2014 - 06/2006
3	MelatoninIBA 05/2008 - 06/2002
3	Dehydroepiandrosterone (DHEA)IBA 03/2004 - 06/2002
2	Endothelins (Endothelin)IBA 05/2021 - 06/2009
2	Antiphospholipid AntibodiesIBA 01/2021 - 01/2018
2	nintedanibIBA 01/2021 - 01/2021
2	sarilumabIBA 01/2020 - 06/2017
2	Dopamine Receptors (Dopamine Receptor)IBA 01/2020 - 10/2014
2	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 10/2014
2	Janus KinasesIBA 01/2020 - 06/2017
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 06/2017
2	baricitinibIBA 01/2020 - 06/2017
2	InterleukinsIBA 09/2018 - 01/2015
2	Collagen Type I (Type I Collagen)IBA 01/2018 - 01/2017

Therapy/Procedure

29	Therapeutics 01/2022 - 07/2002
11	Lasers (Laser) 01/2022 - 06/2010
4	Chronotherapy 01/2016 - 10/2010
2	Off-Label Use 05/2022 - 03/2011